Resolution of Hypoprothrombinemia-Lupus Anticoagulant Syndrome (HLAS) after multidrug therapy with rituximab: a case report and review of the literature.

Abstract

Hypoprothrombinemia associated with a lupus anticoagulant (LA) was first reported in the literature over 50 years ago. The hypoprothrombinemia-lupus anticoagulant syndrome (HLAS) is a rare bleeding diathesis that has been associated with LAs in adult and paediatric patients with systemic lupus erythematosus (SLE) and with transient LAs due to other causes. There are no standard recommendations for treating haemorrhage associated with this syndrome. Herein, we report a patient with SLE and HLAS who achieved a durable remission following treatment with intravenous immune globulin (IVIG), prednisone and rituximab.

• Authors: R D Paschal, A T Neff
• Journal: Haemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 19 Issue 2 Pg. e62-5 (Mar 2013) ISSN: 1365-2516 [Electronic] England
• PMID: 22989209 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: © 2012 Blackwell Publishing Ltd.

Chemical References

• Antibodies, Monoclonal, Murine-Derived
• Glucocorticoids
• Immunoglobulins, Intravenous
• Immunologic Factors
• Lupus Coagulation Inhibitor
• Rituximab
• Prednisone

Topics

• Adult
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Antiphospholipid Syndrome (drug therapy)
• Drug Therapy, Combination (methods)
• Female
• Glucocorticoids (therapeutic use)
• Humans
• Hypoprothrombinemias (drug therapy)
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Factors (therapeutic use)
• Lupus Coagulation Inhibitor
• Prednisone (therapeutic use)
• Rituximab
• Treatment Outcome